阿齐沙坦的临床应用进展

Progress in Clinical Application of Azilsartan

阿齐沙坦为批准用于高血压的第8个血管紧张素Ⅱ受体拮抗剂(angiotensinⅡreceptor antagonist,ARB)。最近的研究表明,阿齐沙坦降低收缩压比其他ARB类药物奥美沙坦、缬沙坦、坎地沙坦和血管紧张素转换酶(Angiotensin-converting enzyme,ACE)抑制剂雷米普利更有效。研究还表明,阿齐沙坦与钙离子拮抗剂氨氯地平合用不仅能有效降低收缩压,而且可以减少外周水肿的发生,与噻嗪类利尿剂氯噻酮联合应用可有效降低收缩压。

Azilsartan is the eighth angiotensinⅡ receptor antagonist(ARB) approved for the treatment of hypertension. Recent studies have demonstrated that azilsartan is more effective than the other ARBs olmesartan, valsartan or candesartan and the angiotensin-converting enzyme inhibitor ramipril at lowering systolic blood pressure. Studies also showed that the combination of azilsartan and the calcium-channel blocker amlodipine is effective at lowering systolic blood pressure, with a reduced incidence of peripheral edema; the combination with the thiazide-like diuretic chlorthalidone is effective in lowering systolic blood pressure.